4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Oncology by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 44704 ongoing clinical trials involving Oncology
Of the 44704 trials,14381 trials are in Phase II
Furthermore, 12258 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Oncology by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Oncology therapy area. The largest number of ongoing clinical trials for indications related to Oncology therapy area is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions involved in drug trials.

National Cancer Institute US: The leading ongoing clinical trial sponsor for indications related to Oncology therapy area

National Cancer Institute US is the top clinical trial sponsor for indications related to the Oncology therapy area.

University of Texas MD Anderson Cancer Center, Sun Yat-sen University, Memorial Sloan Kettering Cancer Center, and Dana-Farber Cancer Institute Inc are a few other notable clinical trials sponsors involved in the Oncology therapy area. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Oncology

Pembrolizumab (Keytruda), Lenalidomide (Revlimid), and Nivolumab (Opdivo, Opdyta) are among the key marketed drugs marketed for the treatment of indications related to the Oncology therapy area.

Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent. It functions via Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist mechanism of action. Keytruda is formulated as lyophilised powder for solution, solution concentrate for intravenous route of administration. Keytruda is marketed for the treatment of several indications including Esophageal Squamous Cell Carcinoma (ESCC), Bile Duct Cancer (Cholangiocarcinoma), Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Esophageal Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Cervical Cancer, Melanoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Head And Neck Cancer, Gastric Cancer, Bladder Cancer, and Small-Cell Lung Cancer. Keytruda was first approved in 2014 and is marketed globally including the US, the UK, France, Canada, and China by Merck & Co Inc and its subsidiaries.

Lenalidomide (Revlimid) is a thalidomide analogue and an immunomodulatory imide drug (IMiD). It functions via Protein Cereblon (CRBN) Activator mechanism of action. It is formulated as hard gelatin capsules for oral route of administration. Revlimid is marketed for the treatment of several indications including T-Cell Leukemia, Follicular Lymphoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, T-Cell Lymphomas, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), and Mantle Cell Lymphoma. Revlimid was first approved in 2005 and is marketed globally including the US, the UK, France, Canada, and China by several prominent pharma giants including Celgene Corp, BeiGene Ltd, and Bristol-Myers Squibb Co.